Chinese low float mania

Check out these explosive movers 💣                                                                                                                                                                                                                                                                                                                                                                                                                 *Together with Brand New IPO Opportunity – TRNR 🏋️ Good morning, 360! Here are our top investing ideas today – and check out our Market News towards the bottom. Be the best prepared trader on the Street! TOP - 2nd day play, closed up over 440% Friday as low float Hong Kong IPO mania rages YGF - Trades over 300% higher in pre-market as traders pile into newly listed Chinese IPO ASND - Up over 15% in pre-market after after FDA issues a Complete Response Letter forTransCon PTH in Hypoparathyroidism *A Message on Behalf of Stock Research Today 🔥 Hot Stock of the Day 🔥 Interactive Strength (Nasdaq: TRNR) After a dismal 2022, IPOs are ROARING again in 2023. Just look at how the top-performing IPOs have been doing so far this year… There is a brand new stock that [just started trading on Friday]( last week that you should look into immediately. The company is Interactive Strength (Nasdaq: TRNR) 🏋️ You already know about their bigger competitors like Peloton, Tonal, and Mirror – but now, TRNR is coming for them! TRNR is looking to dominate the at-home training market by not only offering cutting-edge equipment but also LIVE training from real professional trainers. Not recorded, mass-produced training sessions you might find on Peloton. Do yourself a favor and look into this opportunity by reading the report our friends at [StockResearchToday]( have put together. While you’re at it, get started with your own personalized training session by [visiting their website]( and lock in a huge discount to try it out for yourself! *Sponsored by Lifewater Media. Please see disclosures below. TOP - 2nd day play, closed up over 440% Friday as low float Hong Kong IPO mania rages TOP Financial Group (TOP) is a Hong Kong based, recently listed IPO that conducts an online brokerage company. We mentioned a week ago that Hong Kong based IPOs could start to heat it up (check your email from Friday April 21) and exactly a week later a mania has occurred in these stocks. There are many sympathy plays going as well such as HUDI, MEGL, YGF, HLP, SNTG and QH. Expect major volatility in all these names today. The $64 level has been a support area from after hours Thursday, on Friday and the pre-market this morning so is an important area to watch. Above it, targets to the upside are at $85, $110, and $125. Beyond that there are further targets at $150, $190, $200 and $250. Below $64, there is potential support at $57, $50, $45 and $25 below that. YGF - Trades over 300% higher in pre-market as traders pile into newly listed Chinese IPO YanGuFan International Group (YGF) exploded over 300% in the pre-market as low float China IPO euphoria reaches its peak. Traders piled into YGF this morning after big moves from other recent IPO’s on Friday, and this is one to watch this morning along with other names such as TOP, HUDI, MEGL, HLP, SNTG and QH. YGF exploded front the $10 level this morning and that area now becomes potential support and is one to watch today. Above it, targets to the upside are $15, $19 and $20. Beyond that, $20.88, $23.70, $27 and $29 come into play. Below $10, there is potential support at $4 and a gap to fill at $3.52. ASND - Up over 15% in pre-market after after FDA issues a Complete Response Letter for TransCon PTH in Hypoparathyroidism Ascendis Pharma (ASND) today announced that the U.S. Food & Drug Administration (FDA) has issued a complete response letter (CRL) for the TransCon PTH (palopegteriparatide) New Drug Application (NDA) for the treatment of adults with hypoparathyroidism. In the letter, the FDA cited concerns related to the manufacturing control strategy for variability of delivered dose in the TransCon PTH drug/device combination product. The FDA did not express concern about the clinical data submitted as part of the NDA package and no new preclinical studies, or Phase 3 clinical trials to evaluate safety or efficacy, were requested in the letter. Ascendis will request a Type A meeting with the FDA as soon as possible to agree on the best path forward. The stock is trading 15% higher in pre-market on the news. ASND found support at the $78 level in the pre-market and that should be an important pivot point today. Above it, targets to the upside are at $82 and the pre-market high of $84.50. Beyond that, there is potential resistance at $96 and a gap to fill at $107.22. Below $78, there is potential support at $75, $71.50 and a gap to fill at $69.96. Economic Calendar (EST) 9:45am PMI manufacturing final 10:00am ISM manufacturing index 10:00am Construction spending No Fed Speakers scheduled Earnings for Today (After Market) ADUS, AHT, AIRC, AL, AMKR, AMRC, ANET, AXNX, BKCC, BRX, BSM, CACC, CAR, CF, CHGG, CLAR, CNO, CRC, CSR, CVI, CYH,ETWO, FANG, FCPT, FLS, FLXS, FMC, FWRD, GAIA, HOLX, INST, INVH, JJSF, KIDS, KMT, KRG, LEG, LOGI, LSCC, MED, MFIN, MGM,MSA, MSTR, NSA, NXPI, OGS, OTTR, PDM, PLOW, RE, RIG, RMBS, RYI, SBAC, SCI, SFM, SGRY, SIBN, SOI, SON, STRL, SYK, SYM,TEX, TMDX, TTI, TWO, UAN, VICI, VLD, VNO, VNOM, VRNS, VRTX, VSEC, WWD, ZI Top Headlines MRK Update on FDA Advisory Committee Vote on LYNPARZA® (olaparib) Plus Abiraterone and Prednisone or Prednisolone in First-Line Metastatic Castration-Resistant Prostate Cancer TEVA: Teva and MedinCell Announce FDA Approval of UZEDY™ (risperidone) Extended-Release Injectable Suspension, a Long-Acting Subcutaneous Atypical Antipsychotic Injection, for the Treatment of Schizophrenia in Adults JXJT JX Luxventure Limited Receives Nasdaq Delisting Notice for Failing to Maintain a $1.00 Share Price and Requested and Granted a Hearing Scheduled for May 25, 2023. MANU: Qataris make improved offer for Manchester United worth more than £5bn – TheTimesUK JPMorgan, PNC Bidding for First Republic as Part of FDIC Takeover - (sm WSJ) URGN New Retrospective Study Presented at AUA 2023 Provides Evidence of Similar Outcomes Utilizing JELMYTO® in the Treatment of UTUC of the Ureter and Renal Pelvis VCYT: Findings From Two Large-Scale, Real-World Data Sets Reinforce Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier ENR WMT Energizer, Walmart sued for conspiring to raise battery prices, Reuters PLRX - Pliant Therapeutics Announces Positive Long-Term Data from the INTEGRIS-IPF Phase 2a TrialDemonstrating Bexotegrast was Well Tolerated at 320 mg with Durable Improvement Shown in FVC and Across Multiple Measures NIO: NIO Reports Delivery Of 6,658 Vehicles In April 2023, Increasing By 31.2% Y/Y OVID Ovid Therapeutics Announces Collaboration with Graviton Bioscience, Proven Developers of Selective ROCK2 Inhibitors WAFU Wah Fu Education Group Limited and Nanjing Agricultural University Agreed the Joint Launch of the Comprehensive Evaluation System of Online Education for Self-taught Examination SNY Maze Therapeutics Announces Exclusive Worldwide License Agreement with Sanofi for MZE001, an Oral Substrate Reduction Therapy for the Treatment of Pompe Disease RDNT RadNet’s Quantib B.V. Subsidiary Receives FDA Clearance for its Quantib Prostate™ 3.0 Software RMTI Rockwell Medical Announces Global Expansion into the United Arab Emirates LMST PEOPLES BANCORP COMPLETES ACQUISITION OF LIMESTONE BANCORP AULT: Ault Alliance Announces Extension of Pending Exchange Offer FE: FirstEnergy Announces Proposed Offering of $1.0 Billion of Convertible Senior Notes Due 2026 LLY: Up to 73% of Atopic Dermatitis Patients Taking Lilly s Lebrikizumab Had Improved or Cleared Skin on Face or Hands in New Analysis NBY: NovaBay Pharmaceuticals Fulfills $1 Million Order for NeutroPhase® Skin and Wound Cleanser for China Pioneer Pharma Holdings BMY: Bristol Myers Squibb’s TRANSCEND FL and TRANSCEND NHL 001 Studies of Breyanzi (lisocabtagene maraleucel) in Relapsed or Refractory Follicular Lymphoma and Mantle Cell Lymphoma Meet Primary Endpoint of Overall Response Rate ELDN: Eledon Pharmaceuticals Announces up to $185 Million Financing to Advance Tegoprubart Kidney Transplantation Clinical Trials IMTX Immatics Announces First Bristol Myers Squibb Opt-in of TCR-T Candidate from Ongoing Multi-target Strategic Collaboration NERV: Minerva Neurosciences Announces the NDA Filing for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia FGEN: FibroGen Announces Non-Dilutive Term Loan Financing for up to $150 Million with Morgan Stanley Tactical Value GILT Gilat Receives Multimillion-Dollar Order for Expansion of Advanced Disaster Response Network in Asia SLN: Silence Therapeutics Completes Enrollment in Phase 2 Study of Zerlasiran (SLN360) in Subjects with Elevated Lipoprotein(a) at High Risk of Atherosclerotic Cardiovascular Disease Events BMY: U.S. FDA Accepts for Priority Review Supplemental Biologics License Application and EMA Validates Application for Reblozyl® (luspatercept-aamt) as First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS) To Your Success! Questions or concerns about our products? Email [Support@360wallstreet.io]( © Copyright 2022, RagingBull - Refund Policy - Privacy Policy - Terms & Conditions *PAID ADVERTISEMENT. RagingBull has been paid fourteen thousand dollars by ach bank transfer by Lifewater Media for advertising Interactive Strength Inc. from a period beginning on May 1, 2023 through May 2 of the same year. As a result of this advertisement and other marketing efforts, Raging Bull may receive advertising revenue from new advertisers and collect email addresses from readers that it may be able to monetize. As of the date of this advertisement, the owners of Raging Bull, do not hold a position in Interactive Strength Inc. This advertisement and other marketing efforts may increase investor and market awareness, which may result in an increased number of shareholders owning and trading the securities of Interactive Strength Inc., increased trading volume, and possibly an increased share price of the Interactive Strength Inc. securities, which may or may not be temporary and decrease once the marketing arrangement has ended. FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. This advertisement is for educational and informational purposes only. All material information contained in this advertisement is based on information generally available to the public, which public information is believed to be reliable and accurate. Nevertheless, Raging Bull can guarantee the accuracy or completeness of the information. This advertisement does not purport to be a complete analysis of any company’s financial position. This advertisement or any statements made in it is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular individual. The statements made in this advertisement should NOT be relied upon for purposes of investing in the companies mentioned in this advertisement, nor should they be construed as a personalized recommendation to you to buy, sell, or hold any position in any security mentioned in this advertisement or in any other security or strategy. It is strongly recommended that you consult a licensed or registered professional before making any investment decision. SUBSTANTIAL RISK INVOLVED. Any individual who chooses to invest in any securities of the companies mentioned in this advertisement should do so with caution. Investing or transacting in any securities involves substantial risk; you may lose some, all, or possibly more than your original investment. Readers of this advertisement bear responsibility for their own investment research and decisions, and should use information from this advertisement only as a starting point for doing additional independent research in order to allow individuals to form their own opinion regarding investments. It is easy to lose money investing or trading, and we recommend always seeking individual advice from a licensed or registered professional and educating yourself as much as possible before considering any investments. Our reports/releases are a commercial advertisement and are for general information purposes ONLY. A portion of our business is engaged in the marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use. A portion of RagingBull’s business model is to receive financial compensation to promote public companies. To conduct investor relations advertising, marketing and publicly disseminate information not limited to our websites, email, SMS, push notifications. This compensation is a major conflict of interest in our ability to provide unbiased reporting. Therefore, this communication should be viewed as a commercial advertisement only. Note, we periodically conduct interviews and issue stock alerts that we are not compensated for. These are purely for the purpose of company awareness, and to generate subscription revenues. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Frequently, companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the corporate awareness program ceases. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our website / media webpage. The information in our website / media webpage is believed to be accurate and correct but has not been independently verified and is not guaranteed to be correct. NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Raging Bull, or any of their owners, employees or independent contractors is not currently registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. USE OF FORWARD-LOOKING STATEMENTS. Certain statements made in this advertisement may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. Forward-looking statements often include words such as “believes,” “anticipates,” “estimates,” “expects,” “projects,” “intends,” or other similar expressions of future performance or conduct. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made and are not statements of historical fact. They involve many risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. There is no guarantee that past performance will be indicative of future results. Raging Bull does not undertake an obligation to update forward-looking statements in light of new information or future events. Readers can and should review all public SEC filings made by the companies profiled in the Advertisements at . sec. gov/ edgar/searchedgar/companysearch TRADEMARKS. All trademarks used in this advertisement are the property of their respective trademark holders and no endorsement by such owners of the contents of the advertisement is made or implied. WE MAY HOLD SECURITIES DISCUSSED. Ragingbull.com, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication. [tw]( Update your email preferences or unsubscribe [here]( © 360wallstreet 62 Calef Hwy. #233 Lee, NH 03861, United States [[beehiiv logo]Powered by beehiiv](